Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Syntara Limited ( (AU:SNT) ) has issued an update.
Syntara Limited has announced the successful completion of a Phase 1a study for its next-generation topical anti-fibrotic, SNT-9465, which demonstrated dose-dependent target engagement and a good safety profile. The company is now progressing to a Phase 1b study for hypertrophic scars, with results expected to support an FDA Investigational New Drug application in 2026. This development positions Syntara to potentially offer the first approved pharmacological treatment for skin scarring, addressing a significant unmet medical need and offering an alternative to current costly and painful treatments.
The most recent analyst rating on (AU:SNT) stock is a Buy with a A$0.06 price target. To see the full list of analyst forecasts on Syntara Limited stock, see the AU:SNT Stock Forecast page.
More about Syntara Limited
Syntara Limited is a clinical-stage drug development company focused on creating innovative treatments for skin scarring. The company specializes in developing topical pan-lysyl oxidase inhibitors, with a market focus on providing effective pharmacological solutions for conditions such as hypertrophic and keloid scars.
Average Trading Volume: 2,487,288
Technical Sentiment Signal: Sell
Current Market Cap: A$48.97M
For an in-depth examination of SNT stock, go to TipRanks’ Overview page.